Evidence map›Paper›PMID 42662611›Full record

ArticleGynecologic oncology reports2026

Peri-treatment ctDNA dynamics in locally advanced cervical cancer: pilot study from a safety-net hospital.

Maya Yasukawa, Adrian Kohut, Diana C Joseph, Jaisa Miller, Nicole Hurtado, Nancy Preston, Chrissy Liu, Lindsey Nguy, Vaagn Andikyan, Thomas Rutherford and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Maya YasukawaDivision of Gynecologic Oncology, University of South Florida Morsani College of Medicine, Tampa, FL 33612, USA.
Adrian KohutDivision of Gynecologic Oncology, University of South Florida Morsani College of Medicine, Tampa, FL 33612, USA.
Diana C JosephSurgical Oncology, Tampa General Hospital Cancer Institute, Tampa, FL 33602, USA.
Jaisa MillerSurgical Oncology, Tampa General Hospital Cancer Institute, Tampa, FL 33602, USA.
Nicole HurtadoSurgical Oncology, Tampa General Hospital Cancer Institute, Tampa, FL 33602, USA.
Nancy PrestonSurgical Oncology, Tampa General Hospital Cancer Institute, Tampa, FL 33602, USA.
Chrissy LiuDivision of Gynecologic Oncology, University of South Florida Morsani College of Medicine, Tampa, FL 33612, USA.
Lindsey NguyDivision of Gynecologic Oncology, University of South Florida Morsani College of Medicine, Tampa, FL 33612, USA.
Vaagn AndikyanDivision of Gynecologic Oncology, University of South Florida Morsani College of Medicine, Tampa, FL 33612, USA.
Thomas RutherfordDivision of Gynecologic Oncology, University of South Florida Morsani College of Medicine, Tampa, FL 33612, USA.
Matthew L AndersonDivision of Gynecologic Oncology, University of South Florida Morsani College of Medicine, Tampa, FL 33612, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Real-time kinetics of circulating tumor DNA (ctDNA) during active concurrent chemoradiotherapy (CCRT) for locally advanced cervical cancer (LACC) remain poorly characterized. We evaluated peri-treatment ctDNA dynamics in a real-world safety-net cohort using a commercially available tumor-informed assay. Methods: We retrospectively reviewed serial ctDNA measurements (Signatera) in 17 LACC patients who underwent definitive CCRT, with or without induction chemotherapy and immune checkpoint inhibitor therapy. Patients were classified by longitudinal ctDNA kinetics as Sustained clearance, Persistent/ Results: Baseline ctDNA was detectable in 15 of 17 patients (88%); patients were classified as Sustained clearance ( Conclusions: Detectable ctDNA declined rapidly during CCRT but frequently followed a non-monotonic trajectory. Serial rather than isolated measurements appear necessary to interpret molecular response during active treatment. Prospective studies are warranted to determine whether trajectory-based ctDNA monitoring can improve risk stratification and recurrence detection.

Indexed as

CCRTCervical cancerctDNARecurrence

Identifiers

PMID42662611
PMCPMC13520082

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.